Recent Updates
Recently added Catalysts
TTRX Positive Sentiment

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

Thursday, August 20, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Turn Therapeutics has published new peer-reviewed research demonstrating that its investigational therapy, GX-03, effectively reduces key inflammatory signals linked to skin diseases. The study, published in the journal Life, provides in-vivo evidence supporting the therapeutic potential of GX-03 in treating inflammatory skin conditions. This advancement highlights the company's focus on localized therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • New peer-reviewed research supports the efficacy of GX-03.
  • GX-03 selectively reduces key drivers of skin inflammation.
  • The study provides in-vivo evidence for the therapy's effectiveness.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~18 mo
Low dilution risk
Lead asset
GX-03
Phase 2 · Covid19

Full Press Release Details

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several important inflammatory signals associated with inflammatory skin disease. The study, published in Life, showed that pretreatment with GX-

Frequently Asked Questions

What is GX-03?

GX-03 is an investigational therapy developed by Turn Therapeutics for inflammatory skin diseases.

What does the new research show?

The research shows that GX-03 selectively reduces key inflammatory signals associated with skin inflammation.

Where was the study published?

The study was published in the peer-reviewed journal Life.

What type of evidence supports GX-03's efficacy?

The study provides in-vivo evidence demonstrating the effectiveness of GX-03.

ShareAdd on Google
Tags: TTRX Viatris Investor Conferences Healthcare Turn Therapeutics GX-03 skin inflammation clinical-stage biotechnology inflammatory skin disease
Last updated: Aug 20, 2026

Biotech snapshot

Cash runway
$10M liquidity · $1M/mo burn
~18 mo
Low dilution risk
Lead asset
GX-03Phase 2
Covid19 →